Search Results

Resverlogix Announces Updated Annual and Special Meeting of Shareholders

Resverlogix Corp. (TSX: RVX) (“Resverlogix” or the “Company”) announced today that its Annual and Special Meeting of Shareholders (the “Meeting”) will be held on Wednesday, July 31, 2024, commencing at approximately 1:00 pm (MT), as opposed to as previously scheduled for June 27, 2024.

May 28, 2024

·

3 min read

Resverlogix Announces Two-Year Extension of Debenture and Elimination of Conversion Privileges

Resverlogix Corp. (TSX: RVX) (“Resverlogix” or the “Company”) announced today a two-year extension of the Company’s US$6.0 million secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group Co.

May 13, 2024

·

3 min read

Resverlogix Announces Change to Its Board of Directors.

Resverlogix Corp. (TSX: RVX) (“Resverlogix” or the “Company”) today announced that Shawn Lu has stepped down from the Board of Directors

February 22, 2024

·

2 min read

Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone’s Potential Therapeutic Benefits

Resverlogix Corp. (TSX: RVX) (“Resverlogix”, “the Company”) today announced publication of an article, entitled, “The BET inhibitor apabetalone decreases

January 11, 2024

·

6 min read

Press Releases

Resverlogix Announces Voting Results from the 2024 Meeting of Shareholders and Closing of Debenture Extension

August 1, 2024

·

3 min read

Press Releases

Resverlogix Provides Update Regarding Two-Year Extension of Debenture and Elimination of Conversion Privileges

July 16, 2024

·

3 min read

Business

Resverlogix Announces Voting Results from the 2023 Meeting of Shareholders

Resverlogix Corp. (TSX: RVX) (“Resverlogix”, or the “Corporation”) today held its Annual Meeting of Shareholders (the “Meeting”) in Calgary, Alberta.

June 21, 2023

·

1 min read

Resverlogix Publishes on Apabetalone’s Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy

Resverlogix Corp. (TSX: RVX) (“Resverlogix”) today announced the publication of a peer-reviewed article, entitled “Apabetalone, a Clinical-stage

October 4, 2023

·

5 min read

Resverlogix Announces Warrant Repricing and One-Year Extension

Resverlogix Corp. (TSX: RVX) (“Resverlogix” or the “Company”) announces that certain of its 27,461,157 common share purchase warrants

June 30, 2023

·

3 min read

Resverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes

Amsterdam, Netherlands and Calgary, Alberta--(Newsfile Corp. - August 29, 2023) - Resverlogix Corp. (TSX: RVX) (“Resverlogix”) (TSX:RVX) today announced that new guidelines published by the European Society of Cardiology

August 29, 2023

·

5 min read